Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation

EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors

(2013) F. Bladt et al.   CLINICAL CANCER RESEARCH

The Novel ATP-Competitive Inhibitor of the MET Hepatocyte Growth Factor Receptor EMD1214063 Displays Inhibitory Activity against Selected MET-Mutated Variants

(2013) Michaela Medová et al.   MOLECULAR CANCER THERAPEUTICS

The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response—Biological and Clinical Aspects

(2013) Michaela Medová et al.   Cancers

MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer

(2012) Yan Feng et al.   Journal of Thoracic Oncology

MET: a promising anticancer therapeutic target

(2012) Solange Peters et al.   Nature Reviews Clinical Oncology

Development of c-MET pathway inhibitors

(2011) Xiangdong Liu et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

A direct role for Met endocytosis in tumorigenesis

(2011) Carine Joffre et al.   NATURE CELL BIOLOGY

Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma

(2011) Jianjun Gao et al.   PHARMACOLOGICAL RESEARCH

Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion

(2010) Yoshinari Asaoka et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers

(2010) Ryoichi Onozato et al.   Journal of Thoracic Oncology

Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274

(2009) Yitzhak Zimmer et al.   CANCER LETTERS

Coupling of Mutated Met Variants to DNA Repair via Abl and Rad51

(2008) S. S. Ganapathipillai et al.   CANCER RESEARCH